XML 79 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Share-based Compensation - Assumptions Used in Determining Fair Value of Options (Details) - Stock options - $ / shares
3 Months Ended 12 Months Ended
Jul. 30, 2017
Mar. 31, 2020
Dec. 31, 2019
Stock options, restricted stock and performance stock options      
Options granted (in shares)   1,897,250 2,119,708
Granted (in dollars per share)   $ 1.141  
Weighted average key assumptions used in determining the fair value of options granted      
Estimated dividend yield (as a percent)   0.00%  
Expected stock price volatility (as a percent)   73.65%  
Weighted-average risk-free interest rate (as a percent)   1.00%  
Expected life of option in years   6 years 3 months  
Weighted-average option fair value at grant (in dollars per share)   $ 0.74  
Neos Therapeutics, Inc. 2015 Stock Option and Incentive Plan      
Stock options, restricted stock and performance stock options      
Options granted (in shares)   1,897,250  
Neos Therapeutics, Inc 2018 Inducement Plan | Chief Executive Officer      
Stock options, restricted stock and performance stock options      
Options granted (in shares) 200,000